Form 4: Moderna CLO Klinger's RSU Vesting & Tax Sale

Moderna's Chief Legal Officer, Shannon Thyme Klinger, reported the vesting of 47,190 restricted stock units and the subsequent sale of 22,817 shares for tax obligations.

Summary

• Shannon Thyme Klinger, Chief Legal Officer of Moderna, Inc., reported transactions related to her equity holdings.
• On December 5, 2025, 47,190 restricted stock units (RSUs) vested and converted into an equal number of common stock shares.
• Concurrently, 22,817 shares of common stock were disposed of at a price of $25.49 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Klinger directly beneficially owns 53,231 shares of Moderna common stock.
• Klinger also directly beneficially owns 141,571 derivative securities in the form of restricted stock units.
• The vesting schedule for the RSU award indicates 25% vested on December 5, 2025, with the remaining portion vesting in twelve equal quarterly installments thereafter.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction involving the vesting of restricted stock units and a subsequent sale for tax purposes, which is neutral in terms of company-specific sentiment.

Positives

• The vesting of 47,190 restricted stock units indicates a milestone achieved in the compensation structure for the Chief Legal Officer.
• The transaction demonstrates a routine and expected part of executive compensation, aligning management interests with shareholder value over time.

Negatives

• A portion of the vested shares (22,817 shares) was sold to cover tax liabilities, which is a common practice but reduces the direct equity holding.

Future Outlook

The remaining 141,571 restricted stock units are scheduled to vest in twelve equal quarterly installments following the initial vesting on December 5, 2025.

Industry Context

This filing represents a routine insider transaction related to executive compensation, common across publicly traded companies in the biotechnology and pharmaceutical sectors. It reflects the standard practice of equity-based incentives for key personnel, aligning their long-term interests with company performance.

Comparison to Industry Standards

• The vesting and tax-related sale of restricted stock units by a Chief Legal Officer is a standard practice in executive compensation across the pharmaceutical and biotechnology industries, similar to practices observed at companies like Pfizer, BioNTech, and Johnson & Johnson.
• The structure of equity awards, including multi-year vesting schedules, is a common mechanism to retain talent and incentivize long-term performance, consistent with global benchmarks for executive remuneration.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine compensation event. The sale for tax purposes is a small disposition relative to the company's total outstanding shares.
• Employees: Reflects standard executive compensation practices, which can be a benchmark for other equity award holders.

Next Steps

• The remaining 141,571 restricted stock units will vest in twelve equal quarterly installments after December 5, 2025.

Key Dates

Keywords

Moderna, MRNA, Shannon Thyme Klinger, Chief Legal Officer, SEC Form 4, Restricted Stock Units, RSU vesting, Insider Transaction, Stock Sale, Tax Withholding, Equity Compensation